Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012

Matthias Preusser*, Frank Winkler, Laurence Collette, Sven Haller, Sandrine Marreaud, Riccardo Soffietti, Martin Klein, Jaap C. Reijneveld, Joerg-Christian Tonn, Brigitta G. Baumert, Paula Mulvenna, Dirk Schadendorf, Renata Duchnowska, Anna Sophie Berghoff, Nancy Lin, David A. Cameron, Yazid Belkacemi, Jacek Jassem, Damien C. Weber

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Web of Science)

Abstract

Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients.
Original languageEnglish
Pages (from-to)3439-3447
JournalEuropean Journal of Cancer
Volume48
Issue number18
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Brain metastases
  • Clinical trail
  • Prophylaxis
  • EORTC

Cite this